Skip to main content

Advertisement

Springer Nature Link
Log in

Molecular targets in the National Cancer Institute drug screen

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757–766

    PubMed  Google Scholar 

  2. Boyd MR, Paull KD, Rubinstein LR (1992) In cytotoxic anticancer drugs: Models and concepts for drug discovery and development. In: Datadisplay and analysis strategies for the NCI disease orientedin vitro antitumor drug screen, edited by Valeriote FA, Corbett TH, Baker LH, Kluwer Academic Publishers, Boston, pp 11–34

    Google Scholar 

  3. Paull KD, Hamel E, Malspeis L (1993) Prediction of biochemical mechanisms of action from the in vitro antitumor screen of the National Cancer Institute. In: Cancer Chemotherapeutic Agents, edited by Foye WE, American Chemical Society, Washington, D. C.

    Google Scholar 

  4. Paull KD, Lin CM, Malspeis L, Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52: 3892–3900

    PubMed  Google Scholar 

  5. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088–1092

    PubMed  Google Scholar 

  6. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks A, Scudiero DA, Welch L, Koutsoukos A, Chiausa AJ, Paull KD (1992) Neural computing in cancer drug development: Predicting mechanism of action. Science 258: 447–451

    PubMed  Google Scholar 

  7. Weinstein JN, Myers T, Buolamwini J, Raghavan K, Viswanadhan VN, Licht J, Rubinstein LV, Koutsoukos AD, Kohn KW, Zaharevitz D, Grever MR, Monks A, Scudiero DA, Chabner BA, Anderson NL, Paull KD (1994) Predictive statistics and artificial intelligence in the U. S. National Cancer Institute's drug discovery program for cancer and AIDS. Stem Cells 12: 13–22

    PubMed  Google Scholar 

  8. Chabner BA, Weinstein JN, Paull KD, Grever MR (1994) Cell line-based screening for new anticancer drug. In: Banzet P, Holland JF, Khayat D, and Weil M (Eds.) Cancer Treatment, an Update. Paris: Springer-Verlag France, pp. 10–16

    Google Scholar 

  9. Van Osdol W, Myers TG, Paull KD, Kohn KW, Weinstein JN (1994) Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst 86: 1853–1859

    PubMed  Google Scholar 

  10. Koutsoukos AD, Rubinstein LV, Faraggi D, Kalyandrug S, Weinstein JN, Paul KD, Kohn KW, Simon RM (1994) Discrimination techniques applied to the NCl in vitro antitumor drug screen: Predicting biochemical mechanism of action. Statistics in Medicine 13: 719–730

    PubMed  Google Scholar 

  11. Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58: 584–591

    PubMed  Google Scholar 

  12. Morrison FS, Benjamin R, Amare M, Costanzi JJ, Hussein K, Ryan DH, Balcerzak S, Pendleton OJ (1982) Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. Am J Clin Oncol 5: 645–648

    PubMed  Google Scholar 

  13. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071–1080

    PubMed  Google Scholar 

  14. Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K (1981) Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: A Southwest Oncology Group study. Cancer Treat Rep 65: 427–430

    PubMed  Google Scholar 

  15. Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ (1981) A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779–2788

    PubMed  Google Scholar 

  16. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ (1987) Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 60: 149–155

    PubMed  Google Scholar 

  17. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a Drug Resistance Profile by Quantitation ofmdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Investigations 95: 2205–2214

    Google Scholar 

  18. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Molec Pharmacol 46: 627–638

    Google Scholar 

  19. Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Anable T, Arceci RJ, Durr FE, Greenberger LM (1994) P-glycoprotein mediates profound resistance to bisantrene. Oncol Res 6: 291–301

    PubMed  Google Scholar 

  20. Utsugi S, Demuth S, Hanna N (1989) Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. Cancer Res 49: 1429–1433

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine Branch, Clinical Oncology Program; and Developmental Therapeutics Program; Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA

    Susan E. Bates, Antonio T. Fojo, John N. Weinstein, Tim G. Myers, Manuel Alvarez, Kenneth D. Pauli & Bruce A. Chabner

Authors
  1. Susan E. Bates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio T. Fojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John N. Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tim G. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth D. Pauli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bruce A. Chabner
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Work dedicated to Dr. Haruo Sugano on the occasion of his 70th birthday. The material of this paper was essentially presented at The Tomizo Yoshida Memorial Symposium on Future Perspectives in Cancer Treatment, held commemorating the 20th Anniversary of the Cancer Chemotherapy Center, Tokyo, in April 1993

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bates, S.E., Fojo, A.T., Weinstein, J.N. et al. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 121, 495–500 (1995). https://doi.org/10.1007/BF01197759

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01197759

Keywords

Search

Navigation